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Alpha7 nicotinic acetylcholine receptor (nAChR) has some peculiar kinetic properties. From the literature
of a7 nAChR-mediated currents we concluded that experimentally measured kinetic properties reﬂected
properties of the solution exchange system, rather than genuine kinetic properties of the receptors. We
also concluded that all experimentally measured EC50 values for agonists must inherently be inaccurate.
The aim of this study was to assess the undistorted kinetic properties of a7 nAChRs, and to construct an
improved kinetic model, which can also serve as a basis of modeling the effect of the positive allosteric
modulator PNU-120596, as it is described in the accompanying paper. Agonist-evoked currents were
recorded from GH4C1 cells stably transfected with pCEP4/rat a7 nAChR using patch-clamp and fast
solution exchange. We used two approaches to circumvent the problem of insufﬁcient solution exchange
rate: extrapolation and kinetic modeling. First, using different solution exchange rates we recorded
evoked currents, and extrapolated their amplitude and kinetics to instantaneous solution exchange.
Second, we constructed a kinetic model that reproduced concentration-dependence and solution ex-
change rate-dependence of receptors, and then we simulated receptor behavior at experimentally
unattainably fast solution exchange. We also determined open probabilities during choline-evoked un-
modulated and modulated currents using nonstationary ﬂuctuation analysis. The peak open probability
of 10 mM choline-evoked currents was 0.033  0.006, while in the presence of choline (10 mM) and
PNU-120596 (10 mM), it was increased to 0.599  0.058. Our kinetic model could adequately reproduce
low open probability, fast kinetics, fast recovery and solution exchange rate-dependent kinetics.
 2014 Elsevier Ltd. All rights reserved.95
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1101. Introduction
The a7 subunit containing nicotinic acetylcholine receptor (a7
nAChR) is known as the second most abundant nicotinic receptor
type in the CNS (after the a4b2 type receptor). These receptors
mostly but not exclusively are homopentamers of the a7 subunit.
Their most prominent role within the central nervous system is
probably the pre- and postsynaptic modulation of synaptic function
and plasticity (Albuquerque et al., 2009; Alkondon and
Albuquerque, 2001; Gray et al., 1996; Gu and Yakel, 2011; Lendvai
and Vizi, 2008; Lozada et al., 2012; Rozsa et al., 2008; Vizi and
Lendvai, 1999), which is the basis of their role in cognition (Hurst
et al., 2012; Lendvai et al., 2012; McKay et al., 2007).cetylcholine receptor; PNU-
thylisoxazol-3-yl)urea; SXT,
36 12109423.
All rights reserved.
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g/10.1016/j.neuropharm.2014The a7 nAChR has some unique properties: a high Ca2þ
permeability, which is counterbalanced by extremely fast desen-
sitization, causing a fast onset and decay kinetics and an extremely
low open probability (Williams et al., 2012, 2011).
The aim of this study was to reﬁne the kinetic analysis of the
receptor. In order to clearly see the unusual aspects of a7 nAChR
receptor kinetics, we need to brieﬂy review what is known about
the kinetic properties of this receptor (Section 3.1.). This re-
examination of reported properties, makes it evident that the ki-
netics depends both on agonist concentration and on solution ex-
change rate. The nature of these dependences, and their interaction
will be discussed, together with their possible mechanism. From
the apparent solution exchange rate dependence it follows that
measurements of the intrinsic kinetic properties of the receptor
may be problematic, and experimentally measured kinetics may
misrepresent intrinsic kinetics of the receptor.
One of our aims was to give a more accurate estimation of
intrinsic kinetic properties of a7 nAChRs, i.e., receptor kinetics
undistorted by insufﬁcient solution exchange rate.117
118
119
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NP5392_proof ■ 4 February 2014 ■ 2/15Our second major goal was to propose a plausible kinetic
scheme for major conformational states of the receptor. This is
important if we want to understand the mechanism of receptor
gating behavior: its agonist concentration-dependence, its solution
exchange rate-dependence, and the interaction of the two. As we
will describe in Section 3.3.1., none of the kinetic models thus far
constructed by our group or others could sufﬁciently reproduce
experimental behavior. Furthermore, an acceptable kinetic model
allows the estimation of intrinsic properties, i.e., determination of
approximate rate constants of agonist association/dissociation, re-
ceptor opening, closing and desensitization.
Constructing an acceptable kinetic model was important for
another reason: One of our aims was to study the mode of action of
the positive allosteric modulator PNU-120596.
The mode of action of a modulator can be quantitatively
described if when we can explain which exact conformational
transitions are modiﬁed, and howmuch they are modiﬁed. Does the
modulator affect agonist association, agonist dissociation, activa-
tion, deactivation, desensitization or recovery? In terms of Markov
models: which speciﬁc rate constants are increased or decreased in
modulator-bound states, and by what factor? Results of this study
are presented in the accompanying paper {Szabo, #171}.
Finally, the low open probability during agonist evoked currents
are one of the unique properties of a7 nAChRs, and it is essential
that the kinetic model we construct can reproduce this attribute
also. We therefore aimed to determine peak open probability
values during agonist evoked receptor activation. The number of
open receptors could be deduced from amplitude-variance plots of
agonist-evoked currents, but in the case of the a7 nAChRs the mean
open time is so low, that a signiﬁcant part of the variance is lost due
to unresolvable fast openings. Because the positive allosteric
modulator PNU-120596 has been shown to radically prolong
channel open times, and thereby to induce prolonged tail currents
in the absence of the agonist (daCosta et al., 2011; Williams et al.,
2011), we were able to construct amplitude-variance plots undis-
torted by channel block, or by unresolvably fast openings and
determine open probability values. Details of the mechanism of
action for PNU-120596 are described in the accompanying paper
{Szabo, #171}.
2. Materials and methods
2.1. Materials
Methyllycaconitine and PNU-120596 were obtained from Tocris Bioscience
(Bristol, UK). Cell culture products were obtained from Life Technologies. All other
chemicals were obtained from Sigma.
2.2. Cell culture
GH4C1 cells stably transfected with pCEP4/rat a7 nAChR were obtained from
Siena Biotech S.p.A. (Siena, Italy). Cells were cultured in poly-L-lysine coated Petri
dishes using HAM’s F10 medium supplemented with 15% horse serum, 2.5% fetal
bovine serum, 1% penicillinestreptomycin, 1 mM GlutaMAX, 100 mg/ml Hygromycin
B.
2.3. Electrophysiology
Experiments were performed in whole-cell or outside-out patch conﬁgurations,
using an Axopatch 200B ampliﬁer and the pClamp software (Molecular Devices,
Sunnyvale, CA). Currents were recorded at 70 mV; digitized at 100 kHz (in short
protocols where currents were evoked by choline alone) or at 20 kHz (in longer
protocols where the effects of PNU-120596 were studied) and ﬁltered at 10 kHz. For
illustration and data analysis some of the traces were further digitally ﬁltered off-
line at 2 kHz. Borosilicate glass pipettes (1.3e4.8 MU) were ﬁlled with pipette so-
lution of the following composition (in mM): CsCl 55, CsF 65, EGTA 10, HEPES 10
(pH¼ 7.2). The extracellular solution contained the following (in mM): NaCl 140, KCl
5 CaCl2 2, MgCl2 1, Glucose 5, and HEPES 5, (pH ¼ 7.3). Solution exchange was
performed by the “liquid ﬁlament switch” method (Franke et al., 1987; Jonas, 1995)
using 1.5 mm OD theta glass tubes (Harvard Apparatus, Holliston, MA) and a Bur-
leigh LSS-3200 ultrafast solution switching system. Theta tubes were pulled and
broken to have a tip diameter between 150 and 250 mm. A drop of Sylgard wasPlease cite this article in press as: Pesti, K., et al., Kinetic propert
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014injected close to the tip of both theta glass channels, half-cured, penetrated by a
0.35 mm OD Microﬁl capillary (WPI Inc., Sarasota FL), and cured fully. Tubing was
connected to the inlets of Microﬁl micropipettes. The solution reservoirs were
connected to the pressure control unit of a DAD-12 solution exchange system (ALA
Scientiﬁc Instruments Inc., Farmingdale, NY), this allowed optimization of ﬂow rate
(typicallyw0.2e0.3 ml/min, which corresponded to 5e20 cm/s ﬂow velocity), and
fast exchange of solutions (ﬂow rate increased up to w1 ml/min). The total dead
volume of the tubing from the reservoir to the tip of the theta tube was w150 ml.
Voltage command waveforms for the piezoelectric actuator were written in the
pClamp software, and delivered through an analog output of the Digidata 1322A
interface. In a few experiments the pressure-controlled dual U-tube system (Szasz
et al., 2007) was used for solution exchange, pressure-control was provided by the
same DAD-12 instrument. In addition to the fast drug application systems, a per-
manent laminar ﬂow of extracellular solution at a rate ofw2.5 ml/min was present
in the recording chamber throughout the experiments. The osmolarity values of the
control extracellular solution, as well as the 10 mM ACh and 10 mM choline solu-
tions were set to 320 mOsm, and all other agonist concentrations were made as a
mixture of these.
2.4. Simulations
The simulation was based on a set of differential equations with the occupancy
of each receptor state (i.e., the fraction of the receptor population in that speciﬁc
state) given by the following equation
dSiðtÞ
dt
¼
Xn
j

SjðtÞ*kji  SiðtÞ*kij

where Si(t) is the occupancy of a speciﬁc state at the time t, Sj(t) is the occupancy of a
neighboring state, n is the number of neighboring states, and kij and kji are the rate
constants of transitions between neighboring states. All simulations were per-
formed using Berkeley Madonna v8.0.1 (http://www.berkeleymadonna.com/), to
solve the differential equations using a fourth-order RungeeKutta method. All pa-
rameters were adjusted manually.
2.5. Analysis of data
Curve ﬁtting was performed by the Solver function of Microsoft Excel. The
Bateman function: I(t) ¼ k1/(k1k2) * exp(ek2 * t)  exp(ek1 * t) was used to ﬁt
choline-evoked currents and to obtain apparent rate constants of activation and
desensitization. Decay phases of evoked currents were ﬁt with either mono-
exponential or biexponential functions: I(t) ¼ (ImaxImin) * exp(et/s) þ Imin and
I(t) ¼ (ImaxImin) * [A1 * exp(et/s1) þ A2 * exp(et/s2)] þ Imin, where s1 and s2 are the
time constants, and A1 and A2 are their respective contribution to the amplitude.
Exchange rate dependence plots were ﬁt with linear (y ¼ a*t þ b), monoexponential
(y ¼ a*exp(t*s) þ b) biexponential (y ¼ a1*exp(t*s1) þ a2*exp(t*s2)) or power
(y¼ a*(xþ b)^t) functions; where a, a1, a2, b, s, s1 and s2 are constants, and t is the 10e
90% solution exchange time (SXT). Paired Student’s t test was used for statistical
analysis. A probability level of 0.05 or less was considered to reﬂect a statistically
signiﬁcant difference.
3. Results and discussion
3.1. Background: concentration-dependent and solution exchange
rate-dependent kinetics of a7 nAChR-mediated currents
Rat a7 nAChR expressing GH4C1 cells were used at 2e5 days
after passage. Agonist application was performed by a pressure-
controlled theta tube perfusion system. Whole cells or outside-
out patches were lifted to the mouth of the theta-tube.
3.1.1. Concentration-dependent kinetics
The effect of different concentrations of ACh and choline was
investigated. As it has been previously observed we found that with
increasing agonist concentration: i) the onset kinetics is acceler-
ated, ii) the decay kinetics is accelerated, and iii) the current
amplitude is increased. Examples for the concentration-dependent
kinetics has been shown in several papers, but typically has not
been quantiﬁed. For this reason, we have reviewed these ﬁgures,
measured rise times, and estimated decay time constants (expo-
nential curves were overlaid with the ﬁgures after adjusting axes to
the calibration bars, and time constants were adjusted until the ﬁt
seemed visually acceptable). The results from 9 individual publi-
cations (Alkondon and Albuquerque, 1993; Castro andies and open probability of a7 nicotinic acetylcholine receptors,
.01.034
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NP5392_proof ■ 4 February 2014 ■ 3/15Albuquerque, 1993; Friis et al., 2009; Gopalakrishnan et al., 1995;
Mike et al., 2000; Papke, 2006; Papke and Thinschmidt, 1998;
Puchacz et al., 1994; Williams et al., 2012) together with our cur-
rent data are plotted in Fig. 1. The concentration-dependent change
in onset and decay kinetics is obvious. The relationship between
log(rise time) and log[ACh] was close to linear, while the slope of
the log(decay time constant) vs. log[ACh] plot decreased at high
concentrations. While these observations were true for all studies,
it was strange to see, that time-to-peak values and decay time
constants varied between individual studies by more than three
orders of magnitude. We wondered what the reason might be for
recording currents with such diverse kinetics.
3.1.2. Solution exchange rate-dependent kinetics
In our experiments we observed that solution exchange rate has
a very similar effect on a7 nAChR mediated currents: As the solu-
tion exchange rate was increased: i) the onset kinetics was accel-
erated, ii) the decay kinetics was accelerated, and iii) the amplitude
was increased (see Section 3.2.2.). Could this phenomenon account
for such great differences? We are aware of only one publication
where the effect of solution exchange rate on a7 nAChR-mediated
currents was studied (Fedorov et al., 2012), and in this case it was
only investigated within a narrow range (fourfold change in solu-
tion exchange times). In the literature, however, solution exchange
rates differ by several orders of magnitude. We reviewedFig. 1. Concentration-dependent kinetics of a7 nAChR-mediated currents. Concentration d
panel) obtained from 9 publications. Where data were not given numerically, they were
dependence of ACh-evoked currents were enlarged, axes were adjusted to the calibration
ﬁt seemed adequate.
Please cite this article in press as: Pesti, K., et al., Kinetic properti
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014publications where the solution exchange rate was indicated
(Alkondon and Albuquerque, 1993; Bouzat et al., 2008; Castro and
Albuquerque, 1993; Friis et al., 2009; Gopalakrishnan et al., 1995;
Mike et al., 2000; Papke et al., 2000; Papke and Thinschmidt,
1998). Measured rise time and decay time constants for 1 mM
ACh-evoked currents from these papers, as well as from this cur-
rent study (see Section 3.2.2.) were plotted against solution ex-
change rates. The results (Fig. 2) show an unmistakable correlation
between the measured kinetics of currents and solution exchange
rates.
We believe that the two phenomena are caused by the same
remarkable property of the receptor. As it has been demonstrated
ﬁrst by Papke and Thinschmidt (1998), current amplitude and ki-
netics do not seem to be determined by agonist concentration itself,
but rather by the concentration gradient: the rate of concentration
increase at the onset phase of agonist application. As it has been
shown, the onset and decay kinetics of the current is so fast, that
the peak amplitude occurs already during the early onset phase of
the agonist pulse, well before the solution exchange is complete,
i.e., when the nominal agonist concentration to be perfused has not
yet been reached. The response we measure is not to the nominal
concentration, but to a lower concentration (Papke et al., 2000;
Papke and Thinschmidt, 1998; Uteshev et al., 2002). If we
consider the case when two agonist pulses are given with equal
concentration gradient but different ﬁnal nominal concentration,ependence of 10e90% current rise times (left panel), and decay time constants (right
measured using the ﬁgures of the publications. Figures illustrating concentration-
bar, and overlayed with exponential curves. Time constants were adjusted until the
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Fig. 2. Solution exchange rate-dependent kinetics of 1 mM ACh-evoked currents The
logarithm of 10e90% rise times (black diamonds) and decay time constants (gray
circles) are plotted against the logarithm of 10e90% solution exchange times (SXT).
Data are from 9 papers (see text), including this study. Linear regression lines and
coefﬁcients of determination are shown.
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NP5392_proof ■ 4 February 2014 ■ 4/15receptors would detect the increase in agonist concentration, be
activated and desensitized; consequently, the current would reach
an identical peak and start decaying even before receptors could
“learn” what ﬁnal concentration would be to be applied. Therefore,
the evoked currents would be identical (except for a minor differ-
ence in the late phase of the decay).
The explanation for this phenomenon is, that some of the gating
transitions (opening, closing or desensitization) must be faster than
the fastest experimentally tested solution exchange. When solution
exchange is rate-limiting, it is natural that intrinsic gating of the
receptor cannot be properly resolved.
Careful inspection of concentration-peak amplitude plots in the
literature reveals that neither the increase in amplitude, nor the
acceleration of kinetics could be saturated. The currents keep get-
ting higher in amplitude and faster in kinetics even at supra-
maximal concentrations (i.e., which produce nearly full occupancy
of binding sites at equilibrium) (up to 10 mM ACh (Friis et al.,
2009)). It is typical in the literature that experimenters could not
actually determine maximal amplitude, e.g. (Alkondon and
Albuquerque, 1993; Khiroug et al., 2002; Papke, 2006; Puchacz
et al., 1994; Williams et al., 2011), therefore maximal amplitudes
are only extrapolated when concentration-peak amplitude plots
are ﬁtted with the Hill equation. This compromises the accuracy of
determining EC50 values. (The situation is further complicated by
the channel block caused by the agonist at high concentrations.)
In summary, both higher concentration with the same rate of
solution exchange, and the same concentration with higher solu-
tion exchange rate provide a higher concentration gradient, and
therefore evoke a faster current with higher amplitude. Because the
rate of solution exchange thus far could not reach rates of receptor
gating, the intrinsic kinetics of the receptor could not be resolved.
The question of course is, how fast the solution exchange should be
in order to appropriately record the intrinsic kinetics of the
receptor.
Because of these properties, it is challenging to study a7 nAChRs.
Even collecting simple concentration-response data is problematic:
responses to individual concentrations are distorted by insufﬁ-
ciently fast solution exchange, and determination of the EC50 valuePlease cite this article in press as: Pesti, K., et al., Kinetic propert
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014is uncertain because of the difﬁculty in determining maximal cur-
rent amplitude.
3.1.3. Aims of the investigation
In this study we attempted to address the following questions:
Can we deduce the intrinsic kinetics of the receptor? How fast so-
lution exchange would be required to resolve it experimentally?
We used two approaches to address these questions: extrapo-
lation and simulation.
Although sufﬁciently fast solution exchange has been thus far
unfeasible, we can examine the dependence of agonist-evoked
current characteristics on solution exchange rate. From the solu-
tion exchange rate dependence of peak amplitude, rise time and
decay time constant, these properties can then be extrapolated to
instantaneous solution exchange.
Alternatively, a kinetic model can be constructed which re-
produces both agonist concentration dependence and solution
exchange rate dependence. Once we have a model like this, we can
simulate any solution exchange rate, even if it is technically un-
feasible, and can test the behavior of the channel even at instan-
taneous solution exchange. Here we encountered the problem of
not having an adequate kinetic model. As we will describe in Sec-
tion 3.3.1., none of the available models could correctly reproduce
all kinetic properties of the receptor, therefore one of our aims was
also to construct an improved model of the a7 nAChR.
3.2. Activation and desensitization kinetics of a7 nAChRs as
measured using fast solution exchange
3.2.1. Properties of 10 mM choline-evoked currents
In most experiments we used choline as an agonist, because of
its fast recovery (Mike et al., 2000), and its selectivity for a7
nAChRs. Normalized currents evoked by 10 mM choline are shown
for whole cells and outside-out patches in Fig. 3. Eight cells, where
currents were evoked by U-tube application are shown for com-
parison in Fig. 3A. The peak amplitude in these cells
was 682  126 pA (range: 325 to 1318 pA). The advantage of
the U-tube system is that it can be used for cells attached to the
culture dish. For the theta-tube, whole cells or outside-out patches
were lifted to the mouth of the theta-tube. On the other hand, the
theta tubewas superior in the accuracy of the timing of drug pulses,
and it could also provide somewhat faster solution exchange. For
this reason in the rest of the experiments the theta tube was used
for agonist perfusion. Currents evoked by theta-tube application
are shown for 25 individual cells in Fig. 3B, left panel. The peak
amplitudewas1300.4 233.9 pA (median:937 pA; range:176
to 4511 pA). The distribution of amplitudes, and decay time
constants plotted against 10e90% rise time values are shown in
Fig. 3 middle and right panels, respectively. Whole-cell capaci-
tances ranged from 2.0 to 13.9 pF (5.05  0.49 pF), which corre-
sponds to approximately 200e1400 mm2 cell membrane surface
(Hille, 1992), which means that the magnitude of current per
membrane surface was 2.76  0.48 pA/mm2. Excision of patches
always resulted in a drop in capacitance (<1 pF for all patches), in
which range the accurate measurement of capacitance was not
possible. While all cells were found to express functional a7
nAChRs, not all outside-out patches gave detectable agonist-evoked
responses. Currents evoked by 10 mM choline ranged from 0 to
2675 pA. The mean current amplitude for all 68 patches
was 137.9  46.1 pA, the median was 14.85 pA. The distribution
of amplitudes of currents evoked by theta-tube application of
10 mM choline both in whole-cell and outside-out mode are
illustrated in Fig. 3D. In 28 Of the 68 patches no choline-evoked
current was observed. In 17 patches the current was smaller
than 50 pA, displaying discernible single channel events; fromies and open probability of a7 nicotinic acetylcholine receptors,
.01.034
Fig. 3. Properties of 10 mM choline-evoked currents. Examples for normalized currents (left panel). Distribution of amplitudes (middle panel; on a logarithmic scale) and of decay
time constants (right panel) are plotted against rise time (10e90%). Insets: The same plots on expanded scales. (A) Currents evoked by U-tube application on 8 cells. (B) Currents
evoked by theta-tube application on 25 cells (whole-cell mode). (C) Currents evoked by theta tube application on 16 outside-out patches. Insets in the left panel of (B) and (C) show
Bateman ﬁts for the currents. (D) The distribution of all 25 whole-cell current amplitudes (closed diamonds) and all 68 outside-out patch current amplitudes (open diamonds).
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NP5392_proof ■ 4 February 2014 ■ 5/15these recordings we did not calculate rise times and decay time
constants, for the sake of accuracy. In the rest of the patches
(n ¼ 23) the current was between 50 pA and 2675 pA. Currents
recorded in 16 of these patches are shown in Fig. 3C. (In the other 7
patches 10 mM choline was given only in combination with PNU-
120596, therefore, these were excluded from the analysis of cur-
rent kinetics.) Distribution of rise times, amplitudes, and decay
time constants are shown in the middle and right panels of Fig. 3C.
The uneven distribution of current amplitudes in patches suggests
clustering of receptors. The absence of observable choline-evoked
current did not necessarily mean that the patch contained no re-
ceptors at all, because of the exceptionally low open probability of
a7 nAChRs. Indeed, in the presence of PNU-120596 5 of the 28 non-
responding patches became active, and showed choline-evokedPlease cite this article in press as: Pesti, K., et al., Kinetic properti
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014currents. For whole-cell and outside-out recordings the average
10e90% rise time values were 0.41  0.03 ms and 0.33  0.03 ms;
the average decay time constants were 0.94  0.09 ms and
0.41  0.04 ms, respectively. These results however should not be
understood as true properties of the receptors, because the rate of
solution exchange strongly affected current kinetics (as we discuss
below). It is more appropriate to conclude based on the distribution
of rise times and decay time constants (Fig. 3B and C), that both
could be in the range of 0.1e0.4 ms.
Another way to assess kinetic properties of the receptor is to ﬁt
transition rate constants directly to the recordings. The simplest
scheme for the interpretation of current rise and decay is the
resting-open-desensitized chain of transitions (Bouzat et al., 2008;
Papke, 2010), in which we disregard closing.es and open probability of a7 nicotinic acetylcholine receptors,
.01.034
Scheme 1
K. Pesti et al. / Neuropharmacology xxx (2014) 1e156
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
NP5392_proof ■ 4 February 2014 ■ 6/15This means that only two rate constants (opening “o” and
desensitization ”d”) determine the shape of the current, and the
process is described by the Bateman function (see Methods). If
we ﬁt our experimentally acquired currents with the Bateman
function we can obtain apparent rate constants of opening and
desensitization. These of course do not reﬂect individual transi-
tion rates of real receptors, but are products of association,
dissociation, opening, closing and desensitization reactions.
Nevertheless, the apparent rate constants can be used to char-
acterize current kinetics. The two apparent rate constants were
2561  243 s1 and 2111  146 s1 for whole-cell currents, and
7594  1982 s1 and 2710  441 s1 for outside-out patches.
Bateman functions ﬁtted to the currents are shown in the insets
of Fig. 3B and C. Note that the rise time and decay time constant
of currents described by the Bateman function is insensitive to
whether the opening or the desensitization rate constant is the
higher: if the values of the two rate constants in Scheme 1 are
swapped, only the amplitude and not the kinetics changes
(Papke, 2010). For this reason we cannot attribute one apparent
rate constant to the activation and the other to the desensitiza-
tion, or vice versa. As we have discussed above, it is misleading to
understand these values as mean properties of the receptors,
because solution exchange times varied between individual
patches, and currents which were evoked by slower agonist
application are more distorted. The more appropriate conclusion
is (as we discussed above for rise times and decay time con-
stants), that apparent rate constants could be at least in the range
of 2000 s1e8000 s1, which still might be an underestimation
due to insufﬁcient solution exchange rate.
Although the currents rapidly decayed approaching the
baseline, they did not completely disappear in the continued
presence of agonists, as it has been observed before (Mike et al.,
2000; Uteshev et al., 2002). In the presence of 10 mM of choline a
deﬁnite plateau phase (or “slow current” (Uteshev et al., 2002))
was observed, which was 1.16  0.7% of the peak current. It was
present in all cells (although in cells where the peak amplitude
itself was small, we could not unambiguously determine its
amplitude). At the termination of choline application no
“rebound” current (Papke et al., 2000; Uteshev et al., 2002) was
apparent, the current decayed to baseline with a time constant of
8.67  0.92 ms.
Both unmodulated and PNU-120596-modulated choline-
evoked currents were fully inhibited by 10 nM Methyllycaconitine
(n ¼ 7, data not shown).114
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1303.2.2. Dependence of choline-evoked current properties on solution
exchange rate
As we have discussed, the amplitude and kinetics of currents
is distorted by insufﬁcient solution exchange rate. To assess the
extent of this distortion, we performed experiments in which
solution exchange rate was modiﬁed. Our aim was to see if we
could deduce the intrinsic kinetics of the receptor. We intended
to achieve this by two approaches: extrapolation and modeling.
On one hand, by recording currents evoked by different agonist
exchange rates, we can extrapolate the properties (rise time,
decay time constant and amplitude) of evoked currents to
instantaneous solution exchange. On the other hand, we can
construct a kinetic model of the receptor, which is able to
reproduce the major characteristics of gating (including the ex-
change rate-dependence of current properties), and we canPlease cite this article in press as: Pesti, K., et al., Kinetic propert
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014simulate instantaneous solution exchange. This second approach
is described in Section 3.3.4.
A typical recording where different solution exchange rates
were used is shown in Fig. 4A. Solution exchange rates for indi-
vidual measurements were determined using open-tip junction
potential measurement right after the experiments, without mov-
ing the pipette. Using the fastest voltage ramp to drive the piezo-
electric device 10e90% solution exchange time (in the following
text “10e90% solution exchange time”will be abbreviated as “SXT”)
values ranged from 0.23 to 0.55 ms depending on the geometry of
the theta tube and the position of the pipette. The solution ex-
change rate was then modiﬁed by decreasing the slope of voltage
ramps, which resulted in exchange rates slowed down to 1e3 m
SXT. Decelerated solution exchange resulted in a signiﬁcantly
decreased amplitude.
In the case of whole-cell measurements, open-tip calibration
may underestimate the SXT that receptors at the surface of the cell
encounter, because of the geometry of the cell, and also because of
the unstirred layer in immediate contact with the cell. At high
ﬂow velocity (5e20 cm/s) and with small diameter cells, such as in
our case, this is not expected to cause a major difference (Sachs,
1999), but we wanted to test experimentally the accuracy of
calibration. Previously the fast channel blocker tetramethylpi-
peridine has been used to assess SXT (Uteshev et al., 2002).
Instead of using a channel blocker, we took advantage of the fact
that the agonists choline and ACh also cause channel block at high
concentrations. The highest ratio of channel block was reached by
10 mM of ACh {Szabo, #171}, therefore we used this concentration
for calibration. In the presence of both the agonist and the positive
modulator PNU-120596 receptors re-open from desensitization,
and produce prolonged opening. When we remove only the
agonist, but not the modulator, channels are rapidly relieved from
block, which is reversible upon re-addition of the agonist. Using
the same protocol that we used for agonist application we
removed and re-applied 10 mM ACh in the continuous presence of
10 mM PNU-120596. This whole-cell-10-mM-ACh-unblock-cali-
bration was compared with open-tip-junction-potential-
calibration in n ¼ 7 cells. A typical example is shown in Fig. 4B.
Junction potential calibration and unblock calibration did not
differ signiﬁcantly, however, rise time values of 10 mM ACh-
evoked currents were signiﬁcantly (p < 104, n ¼ 7) lower than
SXT-s measured with either of the calibration methods: The 10e
90% rise time for 10 mM ACh-evoked currents was 18.8  2.6% of
the SXT measured with 10 mM ACh unblock. The current already
peaked when only 12.5  1.9% of the receptors was relieved from
block. This conﬁrms the observation that at high agonist con-
centrations (i.e., when agonist association is not rate limiting)
channel gating is faster than solution exchange, and therefore the
peak is reached even before the receptors could encounter the
ﬁnal concentration.
Amplitude values plotted against SXT values of the calibration
currents are shown for 7 individual cells in Fig. 4C (gray lines).
Amplitudes were normalized to the value measured at 1 ms SXT
(linear extrapolation from the two neighboring data points). Linear
ﬁts predicted that at instantaneous solution exchange, the ampli-
tude would be 1.48  0.15 times (range: 1.08e2.10) the amplitude
measured at 1 ms SXT. This value most probably underestimates
the true value, because the dependence of amplitude on solution
exchange is not likely to be linear. Signiﬁcantly better ﬁt was ach-
ieved using monoexponential functions (gray dotted lines in
Fig. 4C), and the predicted factor was 2.08  0.25 times (range:
1.32e3.27), meaning that at instantaneous solution exchange the
amplitude would be 2.1 times higher than the current evoked by
1 ms SXT. Biexponential ﬁtting caused only negligible further
improvement. In contrast to linear ﬁts, mono- and bi-exponentialies and open probability of a7 nicotinic acetylcholine receptors,
.01.034
Fig. 4. Dependence of agonist-evoked current shape on solution exchange rate. (A) An example for the solution exchange rate, and the evoked currents. Scale bar: 100 pA, 1 ms.
Successive traces are shifted by 1 ms for clarity. Upper panel: Open-tip junction potential measurements were used to measure solution exchange rate, SXT values in this
experiment were 2.3, 1.3, 1.0, 0.6 and 0.35 ms; from light gray to black line. (Currents were scaled for visibility.) Lower panel shows corresponding 10 mM choline-evoked currents.
(B) An example for the two calibration methods. Scale bar: 100 pA, 1 ms. Successive traces are shifted by 2 ms for clarity. Thick lines: open-tip-junction-potential-calibration, thin
lines: 10-mM-ACh-unblock-calibration (co-application of 10 mM ACh and 10 mM PNU-120596 switched to application of 10 M PNU-120596 alone, upon which the channels are
relieved from block caused by ACh). Both calibration curves were normalized for the sake of comparability. Lower panel shows corresponding 10 mM ACh-evoked currents. (CeE)
Plots of 10 mM choline-evoked peak current amplitudes (C), decay time constants (D), and rise times (E) against 10e90% solution exchange times for 7 individual cells (gray lines).
Dotted lines show ﬁts by exponential (C and E) and power (D) functions. Individual parameters of the ﬁtted equations were averaged, and the mean of each parameter was used to
construct the equation that was used for extrapolation (black dotted lines). Open circles indicate the y axis intersection, with its value shown.
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NP5392_proof ■ 4 February 2014 ■ 7/15ﬁts are likely to overestimate the amplitude at 0 SXT, because the
amplitude is not expected to rise further, once the solution ex-
change rate has exceeded the intrinsic gating kinetics of the re-
ceptor. Values of the three parameters of monoexponential
equations (see Section 2.5) ﬁt to individual measurements were
averaged, and the resulting equation is plotted on the ﬁgure (black
line). It intersects the y axis at 2.08, which was essentially the same
value that we got as the arithmetic mean of the seven individual
values at 0 SXT.
Decay time constants for instantaneous agonist applications
were extrapolated in a similar way (Fig. 4D). For linear extrapola-
tion, the predicted decay time constants at 0 SXT ranged between
0.15 and 0.86 ms (0.52  0.16 ms). The extrapolation predicted that
instantaneous application would evoke a current where the decay
time constant is 56.110.2% of the time constant measured at 1 ms
SXT. Using a power function (gray dotted lines in Fig. 4D) produced
a better ﬁt, and predicted similar decay time constants
(0.41  0.12 ms, ranging between 0.16 and 0.83 ms), but a some-
what larger difference between 0 ms and 1 ms SXT: the former was
predicted to be 36.4  10.4% of the latter. Besides individual mea-
surements (gray lines) we also show the curve obtained by least
squares ﬁtting to all points (black line in Fig. 4D). It predicted a
decay time constant of 0.48 ms at 0 ms SXT, which was 41.6% of the
value at 1 ms SXT.
The dependence of rise time on solution exchange rate also did
not appear to be linear (Fig. 4E), this plot was ﬁt with an expo-
nential function. The rise time extrapolated for instantaneousPlease cite this article in press as: Pesti, K., et al., Kinetic properti
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014solution exchange was 0.22  0.03 ms (range: 0.14e0.34 ms). The
extrapolation predicted that at instantaneous exchange the rise
time is 37.4  5.6% of the value at 1 ms SXT.
We supposed that solution exchange rate can only be rate
limiting when agonist association is fast enough. To test this, we
conducted experiments in which the SXT-dependence of 1 and
10 mM of choline, as well as 1 and 10 mM of ACh were compared
using the same cell (n ¼ 5). As expected, 1 mM choline evoked
slower currents with lower amplitude, the kinetics and amplitude
of 1 mM ACh-evoked currents roughly matched those of 10 mM
choline-evoked currents, and 10 mM ACh evoked even faster cur-
rents with higher amplitude. Relative rise times (as compared to
10 mM choline-evoked currents) for 1 mM choline, 1 mM ACh and
10 mM ACh were 4.00  0.91, 1.14  0.22, and 0.67  0.07,
respectively. Relative decay time constants were 3.87  0.55,
1.22  0.15, and 0.79  0.11, while relative amplitudes 0.19  0.02,
0.75  0.06, and 1.54  0.19. The SXT-dependence of 1 mM choline
was nonsigniﬁcant within the 0.2e2.2 ms SXT range, 1 mM ACh-
evoked currents showed SXT-dependence similar to 10 mM
choline-evoked currents, while 10 mM ACh-evoked currents were
the most SXT-dependent.
3.2.3. Recovery from desensitization
We have previously shown using U-tube agonist application
that recovery from desensitization is rapid and agonist-dependent
(Mike et al., 2000). However, this agonist application method is not
ideal for quantitative measurement of recovery, because of thees and open probability of a7 nicotinic acetylcholine receptors,
.01.034
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NP5392_proof ■ 4 February 2014 ■ 8/15considerable jitter in the delay of offset (up to 30 ms with U-tube
application, while it was <0.2 ms for theta tubes). Using theta-tube
agonist application, we measured recovery using short (180 ms)
and long (5 s) pulses. We observed that recovery was somewhat
delayed after the longer pulses, conﬁrming the existence of more
than one desensitized conformational states of a7 nAChRs (Uteshev
et al., 2002; Wang et al., 2012; Williams et al., 2011), and similar
observations using muscle-type (Elenes and Auerbach, 2002;
Reitstetter et al., 1999) and a4b2 nAChRs (Paradiso and Steinbach,
2003). When high concentration of agonist is present for a pro-
longed period of time, receptors seem to reach a “deeper” desen-
sitized state, fromwhich recovery is slower. Recovery could only be
adequately ﬁtted by a bi-exponential function. The fast component
was responsible for about half of the amplitude (55.8  0.03% and
50.4  0.04% for the short and long pulses, respectively) (Fig. 5).
Time constants of recovery after short pulses were found to be
11.41  3.23 and 308.6  39.3 ms, while after long pulses
72.77 18.84 and 1079.3106.3ms (n¼ 8). For long pulses the fast
time constant could not be accurately determined, because the
shortest interpulse interval was 215 ms; bi-exponential ﬁts gave
adequate ﬁts in the range of 10e100 ms. The slow time constant
was, however, signiﬁcantly higher than for the short pulses, no
matter what the fast time constant was chosen to be (p < 0.002,
n ¼ 8). After the long pulses currents recovered only to 92.1  3.1%
of the control current, suggesting the existence of a third, even
slower component of recovery. Least square ﬁts to the averaged
curves (shown in Fig. 5) gave 13.05 ms and 317.3 ms time constants
for the recovery after short pulses, while 83.08 ms and 1073.9 ms
for the recovery after long pulses.
The recovery was signiﬁcantly slower, and could be adequately
ﬁtted with a monoexponential function, when the agonist was
300 mM nicotine. The time constants for the averaged curves were
505.7 ms and 1004 ms, for short and long pulses, respectively
(Fig. 5).100
101
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1083.2.4. Estimation of open probability
The number of receptors in individual outside-out patches was
estimated using nonstationary ﬂuctuation analysis. The method
could not be used for the analysis of currents evoked by the agonist
alone for a number of reasons: First, the rapid kinetics (most of the
activity is over within a few milliseconds) would limit the number
of samples collected for the analysis. Second, because of theFig. 5. Time course of recovery after 10 mM choline (black squares), and 300 mM
nicotine (gray circles) application. Lines show bi-exponential (choline), and mono-
exponential (nicotine) ﬁts. Closed symbols: recovery after short agonist application
(180 ms). Open symbols: recovery after long agonist application (5 s). The inset shows
the same curves plotted against the initial 1600 ms of interpulse intervals on a linear
time scale.
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
Please cite this article in press as: Pesti, K., et al., Kinetic propert
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014extremely short open time a signiﬁcant fraction of openings would
escape detection, and thus part of the variance would be lost due to
ﬁltering. Finally, in the presence of the agonist the amplitudewould
be distorted by channel block. However, when the agonist is co-
applied with PNU-120596, the open times are drastically pro-
longed, and a long (w1 s) tail current occurs after termination of
agonist and modulator perfusion (Fig. 6). During this tail current
the variance is not distorted by channel block (see accompanying
paper for a more detailed discussion), open times are long, there-
fore the variance is not compromised by sampling rate and ﬁltering,
and sufﬁcient number of samples can be collected for analysis. We
ﬁrst determined single channel conductance by making an all-
point amplitude histogram from the ﬁnal part of the decay, and
ﬁtting a sum of Gaussians on the histogram. This made our analysis
more reliable, because we needed to determine only one of the two
variables from the amplitude-variance plot. This compensated for
the fact that the number of consecutively evoked currents used in
the analysis was limited, because we could only use experiments
where the current amplitude was stable. The absence of run-down
was veriﬁed by stability plots for the currents: datawhere R2 values
between time and current amplitude exceeded 0.015 were
excluded from analysis. Single channel amplitude was found to be
6.24  0.17 pA at 70 mV holding potential. This means a
conductance of 89.1 pS, and is in agreement with conductance
values of a7 nAChRs activated by agonists in the presence of PNU-
120596 (daCosta et al., 2011; Gusev and Uteshev, 2010; Kalappa
et al., 2010), or by agonists alone (Castro and Albuquerque, 1993;
Fucile et al., 2002; Mike et al., 2000; Valles et al., 2009). It has
been observed recently, that single-channel amplitudes of currents
evoked in the presence of the positive allosteric modulator TQS did
not exactly match the amplitudes of currents evoked by the agonist
alone, but were larger by 21.5%. This may likely be the case for PNU-
120596 as well, although a statistically signiﬁcant difference has
not been thus far shown (daCosta et al., 2011; Hurst et al., 2005;
Williams et al., 2011). The number of receptors was determined
by ﬁtting the amplitude-variance plots in 5 outside-out patches,
using 21e34 consecutively evoked currents. From the number of
receptors per patch we could conclude that the maximal amplitude
reached in the presence of 10 mM choline and 10 mM PNU-120596
corresponded with 59.9  5.75% of the channels being open
simultaneously, while at the peak of 10 mM choline-evoked cur-
rents (using SXTw1 ms) only 3.3  0.6% of the channel population
was open (supposing equal single channel conductance for choline-
evoked and choline plus PNU-120596-evoked currents). Even if we
suppose a non-equal single channel conductance, the peak open
probability would not be higher thanw4%.
3.3. Interpretation of experimental data in the context of a kinetic
model
3.3.1. The necessity of an improved kinetic model of the a7 nAChR
In order to reach amore thorough understanding of the intrinsic
gating behavior of a7 nAChRs, and of the mechanism of action of
the modulator PNU-120596 (see accompanying paper {Szabo,
#171}), we needed an adequate model that could reproduce the
major properties of the receptor.
Thus far three detailed kinetic models have been proposed
(McCormack et al., 2010; Mike et al., 2000; Papke et al., 2000). We
tested them by performing simulations in a number of experi-
mental conditions. It was obvious that they do not only need a
minor adjustment; we needed to construct a totally new model.
Results of simulations in different experimental protocols are
summarized in Table 1. Most importantly, none of the models was
fast enough to reproduce gating kinetics as it is observed using
submillisecond solution exchange (Bouzat et al., 2008), see alsoies and open probability of a7 nicotinic acetylcholine receptors,
.01.034
Fig. 6. Determination of the number of receptors in a patch using nonstationary ﬂuctuation analysis. (A) An example for subsequent currents evoked by choline and PNU-120596.
For the sake of clarity, only 10 of the total 34 traces are shown. The solid box indicates the region used for all-point histograms, the dotted box indicates the region used for
nonstationary ﬂuctuation analysis. (B) Amplitude variance plot of the decay phase of the current. Based on the least square ﬁt of the quadratic function (thick line) n ¼ 52 receptors
were estimated in this patch.
Scheme 2
Scheme 3
Scheme 4
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NP5392_proof ■ 4 February 2014 ■ 9/15Figs. 3 and 4 of this study. The following major characteristics of a7
nAChR-mediated currents were examined:
- Concentration-dependent amplitude and kinetics of evoked
currents.
- Solution exchange rate-dependent amplitude and kinetics.
- Neither of these could be saturated, not even with agonist
concentrations as high as 10 mM ACh (Friis et al., 2009), or so-
lution exchange rates as fast as 0.1e1 m (Bouzat et al., 2008;
daCosta et al., 2011; Williams et al., 2011).
- At high agonist concentration (1 mM ACh), and at submilli-
second solution exchange (XCR ¼ 0.5 ms), the rise time was
w0.1e0.3 ms, and the decay time constant was w0.3e0.5 ms
(Bouzat et al., 2008), and this current study (Figs. 3 and 4).
- Desensitization was almost complete even at lower concentra-
tions. At high concentrations the plateau current amplitude was
w1% of the peak amplitude.
- The concentration-net-charge-ﬂux plot differed from the
concentration-peak amplitude plot in the following aspects: i) it
had a lower EC50 value, ii) it had a higher slope, and iii) it had a
deﬁnite plateau (Friis et al., 2009; Komal et al., 2011; Papke,
2006).
- Fast deactivation at the end of agonist application. No rebound
current was seen at the end of agonist application with the two
endogenous agonists.
- Recovery was fast and agonist-dependent.
Table 1 summarizes the performance of the three earlier
models, and our current model. In the upper part of the table, we
present numerical results of simulations. Italic fonts indicate results
which are evidently unacceptable. The lower part summarizes the
major qualitative features.
In summary, the Mike et al., 2000 model could not reproduce
the low open probability, the McCormack et al., 2010 model pro-
duced currents that decayed very slowly, and the Papke et al., 2000
model showed no SXT-dependence, did not recover fast, and did
not reproduce the concentration-net charge plot. The reason why
the Mike et al., 2000 model could reproduce the low open proba-
bility, is in the topology of the model, which will be discussed in the
next section.
3.3.2. Alternative topologies for the kinetic model
The three major states of the receptor that must be considered
are resting, open and desensitized conformations. Bidirectional
transition between any two of these states may be possible;
therefore a general scheme that describes the receptor (at a certain
agonist occupancy level) could be the following:Please cite this article in press as: Pesti, K., et al., Kinetic properti
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014where “ro” and “or” are the opening and closing rates, respectively;
“od” and “rd” are rates of desensitization, “do” and “dr” are rates of
recovery from desensitized state. Because there are redundant
pathways of desensitization and recovery Scheme 2 can be
simpliﬁed without losing the experimentally observed ability to
open, close, desensitize and recover. There are twoways to simplify
Scheme 2:Although we have used both the R-O-D (Mike et al., 2000) and
the O-R-D (McCormack et al., 2010) topologies before, we have not
systematically investigated if they are equally adequate for
modeling this speciﬁc receptor. We tested their performance on aes and open probability of a7 nicotinic acetylcholine receptors,
.01.034
Table 1
Summary of the three detailed kinetic models of a7 nAChRs from the literature, and our current model. Kinetic models were reconstructed, and simulations with the same
protocols were run using all four models. Concentration-dependence of amplitude, kinetics and net charge ﬂow was investigated, as well as SXT-dependence of kinetics and
amplitude. Upper eight rows summarize main quantitative data, italic fonts indicate data that are evidently inappropriate. Lower 15 rows show most important qualitative
properties. Q5
Properties of simulated currents: Model:
Mike et al., 2000 Papke et al., 2000 McCormack et al., 2010Q6 Current study
EC50 concentration-peak amplitude plot (mM) 112.8 79.6 122.7 306.7
nH concentration-peak amplitude plot 1.45 2.40 1.53 1.48
EC50 concentration-net charge plot (mM) 7.07 76.7 64.8 11.81
nH concentration-net charge plot 2.88 2.48 1.67 3.07
peak popen(1 mM ACh-evoked current, SXT ¼ 2 ms) 0.27 0.0029 0.018 0.025
10e90% rise time (ms) (1 mM ACh, SXT ¼ 2 ms) 0.79 0.77 1.58 0.47
sdecay (ms)(1 mM ACh, SXT ¼ 2 ms) 1.20 0.74 108 0.23
Amplitude ratio: SXT ¼ 1.5 ms/SXT ¼ 6 ms (1 mM ACh) 1.82 0.68 1.04 4.95
Concentration-dependent acceleration of onset Yes Yes Yes Yes
Concentration-dependent acceleration of decay Yes Yes Yes Yes
Low open probability No Yes Yes Yes
Almost complete desensitization at 100 mM ACh Yes No Yes Yes
Onset and decay kinetics fast enough No No No Yes
Concentration e net charge ﬂux plot: lower EC50 Yes No Yes Yes
Concentration e net charge ﬂux plot: higher slope Yes No No Yes
Concentration e net charge ﬂux plot: reaches plateau No No Yes Yes
Concentration e peak amplitude plot: keeps increasing Yes No Yes Yes
Faster kinetics with faster solution exchange Yes Yes Yes Yes
Amplitude increases with faster solution exchange Yes No No Yes
Absence of rebound current Yes No Yes Yes
Fast recovery No No No Yes
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NP5392_proof ■ 4 February 2014 ■ 10/15simple transient current with kinetic parameters similar to exper-
imentally acquired agonist-evoked currents.
In the triangular model we set “do” and “dr” to zero for the sake
of simplicity (recovery is negligible in the presence of an agonist).
We know that the mean open time is w50 ms, therefore we con-
strained the model so that the sum of closing rates (or þ od) was
20,000.
Thus we had three free parameters, “ro”, “rd” and “or”. We ﬁrst
intended to reproduce an agonist-evoked current using the trian-
gular model, and then see if the simpliﬁed models can still produce
the same current. In experiments (Fig. 3C) we saw that the rise time
could be as fast as <100 ms, and the decay time constant as low as
w200 ms. Using the parameters ro ¼ 1000 s1, or ¼ 10,000 s1,
od ¼ 10,000 s1, rd ¼ 5000 s1, the rise time was 67 ms, the decay
time constant 212 ms, and the peak open probability 0.03 (which is
similar to experimental data, as discussed below). We tried to
reproduce this simulated current curve using the two simpliﬁed
models, by ﬁtting the simulated current curve produced by both
simpliﬁed models to this one. The model with the O-R-D topology
could exactly replicate the curve with the parameter values
ro¼ 1000 s1, or ¼ 20,000 s1 and rd¼ 5000 s1. The R-O-D model,
however, was unable to replicate the curve (Fig. 7A) (the kinetics
itself could be exactly reproduced, but only when we allowed
higher open probability). This is reasonable, because maximizing
the open probability at 0.03 would mean that we try to force all
receptors through a very narrow bottleneck. In fact even with the
triangular topology this can only be done when the ro/rd ratio is
low enough (it was 0.2 in this case). Whenwe constrained the ro/rd
ratio to be 0.25, 0.5 or 1, the current could not be replicated. Best ﬁts
to the same curve with the constraint of ro/rd ¼ 0.25, 0.5 and 1 are
shown in Fig. 7B.
In summary, in the case when fast kinetics of currents and low
open probability coexist (such as in the case of the a7 nAChR),
triangular topology can be simpliﬁed to the O-R-D, but not to the R-
O-D topology. When either of these conditions is not required, both
topologies are possible. Fig. 7C and D illustrate these cases. In
Fig. 7C the ro/rd ratiowas changed: ro¼ 5000 s1 and rd¼ 1000 s1.
The resulting current with peak open probability ¼ 0.16 could bePlease cite this article in press as: Pesti, K., et al., Kinetic propert
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014reproduced with both O-R-D (ro ¼ 5580 s1, rd ¼ 3862 s1), and R-
O-D (ro ¼ 4196 s1, or ¼ 2823 s1 and od ¼ 17,177 s1) models.
Fig. 7D illustrates a simulated current with the same low open
probability but slower kinetics: (ro¼ 750 s1, rd¼ 250 s1), and the
curves produced by the simpliﬁed models ﬁtted to it. The ﬁtted
parameters were: ro¼ 763 s1, rd¼ 635 s1 for the O-R-D topology,
and ro ¼ 688 s1, or ¼ 1563 s1 and od ¼ 18436 s1 for the R-O-D
topology.
In summary, considering the open probability and the kinetics of
a7 nAChR-mediated currents evoked by high agonist concentra-
tion, we can conclude that the majority of receptors must desen-
sitize from closed state. Therefore the O-R-D topology clearly
represents a7 nAChRs better than the R-O-D topology.
We have one more reason for thinking that models with O-R-D
topology might indicate the behavior of the receptor better. The
mean channel open time was not found to depend on agonist oc-
cupancy (Bouzat et al., 2008; daCosta et al., 2011; Mike et al., 2000).
This could be explained by supposing a single open state (Papke
et al., 2000), but simulations with single-open-state-models pro-
duced concentration-response curves, which reach a maximum
and then decay again, which is not what we observed experimen-
tally. We could only reproduce acceptably concentration-response
curves with multiple open state models. The observation that
mean open times do not noticeably differ depending on the number
of bound agonists, requires that in the model the sum of rate
constant values for transitions leaving the open state is constant
throughout all agonist occupancy levels. It is more prudent to
suppose that or’ in Scheme 3 is constant (does not depend on the
number of bound agonist molecules), than to suppose that in
Scheme 4, where "od’’ must radically increase at higher agonist
occupancy levels, the parallel decrease in "or’’ just happens to
exactly balance that.
3.3.3. Construction of the model of the a7 nAChR
The topology of the model is illustrated in Scheme 5. The dif-
ferences compared to our previous models are: i) in order to better
reproduce concentration-dependent kinetics and sensitivity to
solution exchange rate, we included all six agonist occupancy levelsies and open probability of a7 nicotinic acetylcholine receptors,
.01.034
Fig. 7. Comparison of alternative topologies for the kinetic scheme. Schematic representation of topologies refer to Schemes 2e4. Small numbers indicate the ratios between “ro”
and “rd” rate constants. Scale bars: 0.01 (open probability), 0.1 ms. (A) Fast-kinetics-low-open-probability simulated current produced by the triangular model (light gray line) could
be ﬁtted by the O-R-D, but not the R-O-D topology. (B) Importance of “ro”e“rd” ratio in triangular models. Light gray line shows the same simulated current shown in (A), with ro/
rd ¼ 0.2. Darker gray and black lines show ro/rd ratios: 0.25, 0.5 and 1, which were unable to reproduce fast-kinetics-low-open-probability simulated currents. (C) Fast-kinetics-
high-open-probability simulated currents could be adequately reproduced by both simpliﬁed topologies. (Note the difference in the scale bar) (D) Slow-kinetics-low-open-
probability simulated currents also could be reproduced by both alternative models.
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NP5392_proof ■ 4 February 2014 ■ 11/15(from 0 to 5), ii) we introduced a slow desensitized state (“S”), iii)
we readjusted parameters to ﬁt solution exchange rate-dependent
kinetics. Including an additional desensitized state was also
necessary in order to tackle the problem of PNU-120596-sensitive
and insensitive desensitized states (Williams et al., 2011). We did
not attempt to identify the number of distinct desensitized states,
and to perform a kinetic characterization of each individual state.
There are most probably more than only two distinct states, as it
was found in muscle-type nAChRs (Elenes and Auerbach, 2002).Q2
Scheme 5
106
107
108
109
110
111
112
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114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130The model is MonodeWymaneChangeux type model, i.e., it is
constructed in a way that the same constants (denoted “allosteric
factors”, X and Y) determine differences in afﬁnity between
different conformations and differences in gating equilibriaPlease cite this article in press as: Pesti, K., et al., Kinetic properti
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014between different agonist occupancy levels (i.e., if desensitized
conformation has an X times higher afﬁnity than resting confor-
mation, then binding of one agonist molecule increases the pro-
pensity of resting receptors to desensitize exactly X-fold). The
constant Z determines only the changes in opening rates upon
agonist association. Closing rates were chosen to be constant for all
agonist occupancy levels, because mean open times were found to
be similar at all agonist concentrations (Bouzat et al., 2008; daCosta
et al., 2011; Mike et al., 2000). For the sake of simplicity, we used
the same X, Y and Z factors for all ﬁve agonist binding steps. Using
this principle the whole model can be built up using only 11 free
parameters (shown in shaded bold fonts in Scheme 5). Values of
parameters and calculation of rate constants are given in Table 2.
3.3.4. Simulated agonist evoked currents
Concentration-dependence of simulated currents is illustrated
in Fig. 8A. The 10e90% solution exchange rate used in this simu-
lation was 2 ms. The plateau phase and the deactivation after
agonist application (the ‘slow’ and ‘delayed’ current component
(Uteshev et al., 2002)) are shown in the inset on a 100 enlarged
scale. Concentration-peak amplitude and concentration-net charge
plots are shown in Fig. 8B, together with the Hill equation ﬁts. For
peak amplitudes the values of best ﬁt were EC50 ¼ 1236 mM,
nH ¼ 1.61, for net charge EC50 ¼ 134.6 mM, nH ¼ 2.30. The concen-
tration dependence of rise times and decay time constants (Friis
et al., 2009; Gopalakrishnan et al., 1995; Mike et al., 2000; Papke
and Thinschmidt, 1998) were qualitatively reproduced, as well as
the plateau current and the decay after the end of agonist appli-
cation. We did not aim to ﬁt parameters to the exact quantitative
properties of experimentally measured currents, because that
would have required adjustment of several unknown parameters.
For example, allosteric factors X, Y and Z are most likely not con-
stant for each agonist binding step. It has been proposed that at
medium levels of agonist occupancy receptors favor opening, whilees and open probability of a7 nicotinic acetylcholine receptors,
.01.034
Table 2
Rate constants (left column), their calculation (middle column) and their values
(right column) for Scheme 5. Rate constants are in s1 units, with the exception of
association rates (a1ea5), which are in s1 mM1 units. Free parameters are in bold
font.
X 5
Y 2
Z 20
a1 50
a2 ¼a1*4/5 40
a3 ¼a1*3/5 30
a4 ¼a1*2/5 20
a5 ¼a1/5 10
dr1 5000
dr2 ¼dr1*2 10000
dr3 ¼dr1*3 15000
dr4 ¼dr1*4 20000
dr5 ¼dr1*5 25000
dd1 ¼dr1/X2 200
dd2 ¼dr2/X2 400
dd3 ¼dr3/X2 600
dd4 ¼dr4/X2 800
dd5 ¼dr5/X2 1000
ds1 ¼dd1/Y2 50
ds2 ¼dd2/Y2 100
ds3 ¼dd3/Y2 150
ds4 ¼dd4/Y2 200
ds5 ¼dd5/Y2 250
o1 0.05
o2 ¼o1*Z 1
o3 ¼o1*Z2 20
o4 ¼o1*Z3 400
o5 ¼o1*Z4 8000
c1-5 20 000
d0 5
d1 ¼d0*X 25
d2 ¼d0*X2 125
d3 ¼d0*X3 625
d4 ¼d0*X4 3125
d5 ¼d0*X5 15625
r0 5000
r1 ¼r0/X 1000
r2 ¼r0/X2 200
r3 ¼r0/X3 40
r4 ¼r0/X4 8
r5 ¼r0/X5 1.6
s0 0.02
s1 ¼s0*Y 0.04
s2 ¼s0*Y2 0.08
s3 ¼s0*Y3 0.16
s4 ¼s0*Y4 0.32
s5 ¼s0*Y5 0.64
rs0 1
rs1 ¼rs0/Y 0.5
rs2 ¼rs0/Y2 0.25
rs3 ¼rs0/Y3 0.125
rs4 ¼rs0/Y4 0.0625
rs5 ¼rs0/Y5 0.03125
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NP5392_proof ■ 4 February 2014 ■ 12/15at high levels they favor desensitization (Papke et al., 2000). This
mechanism could be approached by deﬁning agonist occupancy
level-dependent allosteric factors. However, the current model
showed that all major properties of the behavior of a7 nAChRs
could be qualitatively reproduced with this simple 11-free-
parameter-model. Pulse duration-dependent changes in recovery
rate suggest that S states are somewhat more absorbing than D
states, and the slow kinetics suggests that a high energy barrier
must be constructed for the D to S transition. Our parameters as
shown in Table 1 qualitatively reproduced bi-exponential, pulse
duration-dependent recovery kinetics. Solution exchange rate
dependence is shown in Fig. 8C. We found a dependence that was
similar to experimental observations. Instantaneous application of
10 mM choline produced simulated currents with 0.133 ms rise
time (10e90% timewas 0.072ms), and the decay time constant wasPlease cite this article in press as: Pesti, K., et al., Kinetic propert
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.20140.288 ms. We asked the question how much an experimentally
observed current is distorted. In Fig. 8Dwe plotted the properties of
simulated currents on the ﬁgures of experimental data (the same
data as shown in Fig. 4CeE). We show simulations of 10 mM
choline-evoked currents at SXTs: 0.016, 0.031, 0.063, 0.125, 0.25,
0.5, 1 and 2 ms. When we compared simulated currents evoked by
quasi-instantaneous (0.016 ms) solution exchange “(Inst)”, to a
1 ms SXT “(1 ms)”, amplitude (Inst) was 2.00 times higher than
amplitude (1 ms). This is similar to the value (2.08 times higher) we
obtained by extrapolation using exponential equations. We could
observe that solution exchange faster than about 60e80 ms did not
cause further signiﬁcant change in current characteristics. We
found the decay time constant to be less sensitive to solution ex-
change rate in simulations (Fig. 8D): The decay time constant (Inst)
was 79.3% of s(1 ms) in simulations, while the extrapolated s(Inst)
was 41.6% of the experimental s(1 ms). Overestimation of the rise
time was estimated to be similar by simulations and extrapolation:
rise time (Inst) was estimated to be 35.1% and 37.4%, respectively
(Fig. 8D). In order to summarize the prediction by simulation and
extrapolation in a straightforward manner, we illustrate the 10 mM
choline-evoked simulated current at 1 ms SXT and at 0.016 ms
(quasi-instantaneous) SXT, as well as a simulated current, where
the parameters were adjusted to match the amplitude and kinetics
predicted by extrapolation to instantaneous solution exchange.
The simulations also gave an estimation on how fast the solution
exchange should be in order to correctly resolve the intrinsic ki-
netics of the receptor. Using our current parameters (Table 1), 60e
80 ms SXT was sufﬁciently fast, which means that recording of
undistorted intrinsic kinetics is experimentally attainable
(Auzmendi et al., 2012; Liu and Dilger, 1991; Sachs, 1999).
As we have discussed in Section 3.2.2., at lower concentrations
the SXT dependence was weaker, and (at 100 mM choline it vas
virtually absent). On the other hand, 10 mM ACh-evoked currents
were more SXT dependent. The reason for this could be that at
lower concentrations, instead of solution exchange rate, association
rate becomes rate limiting. In general, at lowagonist concentrations
undistorted currents could be evoked by slower solution exchange,
while high concentrations evoked currents which were more
strongly SXT-dependent. This situation led to a curious phenome-
non: Simulated concentration-peak amplitude curves diverged at
higher concentrations (Fig 8F), which produced an apparent shift of
EC50 values depending on SXT on normalized concentration-peak
amplitude curves: with faster solution exchange the afﬁnity of
the agonist appeared to decrease (Fig. 8G). Concentration-net
charge plots, on the other hand, were essentially insensitive to
solution exchange rate in the range of 2e20 ms SXT (Fig. 8H).4. Conclusions
A review of the literature of a7 nAChR-mediated currents in-
dicates that measured kinetics is distorted by limited solution ex-
change time, in fact the kinetic parameters reﬂect properties of the
solution exchange system much more that the genuine properties
of receptors. We propose that peak amplitudes do not reﬂect the
concentration of the agonist perfused, but rather the slope of
agonist concentration increase at the beginning of agonist appli-
cation, From this it follows that maximal peak amplitude cannot be
reached in concentration-response experiments, and therefore
EC50 values of agonists are bound to be inaccurate. This raises the
question, whether the intrinsic kinetic properties of a7 nAChRs can
be determined, how fast solution exchange would be needed to
accomplish this, and what the EC50 values in such case would be.
These problems also challenged us to construct a kinetic model of
a7 nAChRs, which could reproduce major characteristics ofies and open probability of a7 nicotinic acetylcholine receptors,
.01.034
Fig. 8. Simulated currents using the model shown in Scheme 5. (A) Currents evoked by 10, 31.62, 100, 316.2, 1000, 3162, 10000 and 31623 mM choline. Scale bar: 1 ms, 0.01 (fraction
of receptors in open states). Inset shows the same simulated currents on a hundred-fold enlarged scale. Scale bar: 1 ms, 0.0001 (fractional occupancy of open states). (B)
Concentration-peak amplitude (ﬁlled symbols) and concentration-net charge (open symbols) plots made from the currents shown in (A). Thick lines indicate Hill equation ﬁts on
the data. (C) Solution exchange rate-dependence of current kinetics and amplitude. Solution exchange rates (upper traces) were chosen to reproduce those shown in Fig. 4. SXT
values were 2.3, 1.3, 1, 0.6 and 0.35 ms (from light gray to black). Lower traces show simulated currents (occupancy of open states). Currents were shifted by 1 ms for visibility. Scale
bar: 1 ms, 0.01 (fractional occupancy). (D) Relative amplitude, rise time and decay time constant values of simulated currents, plotted against SXT, shown together with corre-
sponding experimental data (see Fig. 4CeE). (E) Simulated currents evoked by 1 ms SXT (dark gray line), and by quasi-instantaneous (SXT ¼ 0.016 ms) solution exchange (black
line), as well as reconstruction of the current predicted by extrapolation (light gray line). (F) SXT-dependence of concentration-peak amplitude curves. The maximal occupancy of all
open states was plotted against choline concentration, when agonist application with ﬁve different SXTs were simulated. (G) SXT-dependence of normalized concentration-peak
amplitude curves. (H) SXT-dependence of normalized concentration-net charge curves.
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NP5392_proof ■ 4 February 2014 ■ 13/15experimentally studied receptors, and which might provide an
insight into their operation.
In this study we attempted to deduce the intrinsic kinetics of a7
nAChRs, and to reﬁne existing kinetic models used for simulation of
receptor behavior. Based on the experiments and simulations, we
propose the following major conclusions:Please cite this article in press as: Pesti, K., et al., Kinetic properti
Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neuropharm.2014From our simulations we propose that a w60e80 ms SXT (10e
90% solution exchange time) would be required to acceptably
resolve intrinsic receptor kinetics when 10 mM choline is used as
an agonist. In general, higher agonist concentrations require
shorter SXT. Our experiments and simulations suggest that at 1 ms
SXT 1 mM choline-evoked currents fairly well represent thees and open probability of a7 nicotinic acetylcholine receptors,
.01.034
Q3
Q4
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NP5392_proof ■ 4 February 2014 ■ 14/15intrinsic kinetics of the receptor, while 10 mM choline-evoked
currents are remarkably distorted: Compared to 1 ms SXT, instan-
taneous solution exchange would evoke a current which has an
amplitude w2 higher (reaching a peak open probability of
w0.07), a rise timew2.7 times shorter (w0.1e0.2 ms), and a decay
time constant w1.25e2.7 time lower (0.2e0.5 ms).
Using theta tubes allowed determination of the recovery rate
with much more accuracy, than U-tube application in a previous
study on native receptors (Mike et al., 2000). Within 1 s the re-
covery was essentially complete after a short pulse of choline. The
recovery, however, was both agonist-dependent, suggesting that
agonist dissociation was rate limiting; and pulse duration-
dependent, which conﬁrmed the presence of more than one
desensitized states.
Currents evoked by 10 mM choline, with w1 ms SXT, evoked a
current with peak open probability of 0.033, a uniquely low value
among receptor ion channels. In the presence of 10 mM PNU-
120596, open probability could be as high as 0.6.
A comparative simulation study of published kinetic models
showed that the model we describe in this study is the ﬁrst kinetic
model that can adequately reproduce low open probability, fast
kinetics, fast recovery and solution-exchange-rate-dependent ki-
netics, as these properties are observed experimentally. By simu-
lations we also provided evidence that at high agonist
concentration the majority of the receptor population must reach
desensitized state without prior opening.
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